Antibody Drug Conjugates Contract Manufacturing Market (By Linker: Cleavable, Non-cleavable; By Condition: Myeloma, Lymphoma, Breast Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global antibody drug conjugates contract manufacturing market was valued at USD 11.04 billion in 2022 and it is predicted to surpass around USD 37.15 billion by 2032 with a CAGR of 12.9% from 2023 to 2032.

Key Pointers

• The myeloma segment dominated the industry and accounted for the largest revenue share of more than 49.5% in 2022.
• The cleavable linker segment dominated the industry in 2022 and accounted for the highest share of more than 56.03% of the overall revenue.
• In terms of region, Asia Pacific dominated the global industry in 2022 and accounted for the maximum share of more than 40.18% of the overall revenue.

The industry is anticipated to witness significant growth over the forecast period on account of the increasing prevalence of cancer, rising demand for biologic therapy, and the challenges associated with antibody drug conjugate (ADC) manufacturing, which contribute to the demand for contract manufacturing. During Q1 and Q2 of 2020, due to the global COVID-19 pandemic, the supply chain was disrupted due to stay-at-home orders by governments across the globe to control the spread of the virus.

Due to these reasons, manufacturing organizations were working with reduced capacity. This hampered the industry's growth slightly. However, beginning in Q3, manufacturing operations were resumed, and many companies implemented strategies, such as expansions to improve their ADC manufacturing capacities. Such actions benefited the industry in 2020. The cases of cancer are rising steadily. This is likely to boost the demand for potential ADCs for cancer treatment in the coming years.

Many cancer medicines have toxicities that cause substantial side effects, thus, limiting the dosage and efficacy of these medications is placing a significant burden on patients. An ADC can help reduce some of these complications. ADCs enable the delivery of a particular medication dosage to a specific site of interest. They are most often used in oncology when a large medication dosage is required at the tumor site but not in nearby tissue. These factors are supporting the demand for ADC for cancer treatment and thus contribute to its demand for contract manufacturing. Manufacturing ADC is a complicated process, and owing to this, biopharmaceutical companies are partnering with Contract Manufacturing Organizations (CMOs).

CMOs have technical knowledge in conjugation and linker creation, as well as in solid platforms. Collaborating with CMOs decreases the time for ADCs to reach the market since they can handle all stages, such as conjugation, scale-up, commercial production, and ADC fill-finish operations, saving time in scheduling and testing. Moreover, ADC CMOs are constantly trying to improve their bioconjugation and manufacturing capabilities to provide their clients with high-quality ADCs. For instance, in October 2022, CMO Lonza partnered with the biotechnology company, Singzyme.

As per the partnership, Lonza could use Singzyme’s enzymatic conjugation platform for developing ADC more efficiently. Such collaborations are expected to improve the demand for ADC CMO activities and hence support industry growth. According to the European Pharmaceutical Review (EPR), as of 2021, over 14 ADCs were commercially approved globally. The EPR also states that over 140 ADCs are currently under development. This is expected to create opportunities for manufacturing ADCs post-pandemic and, thus, support market growth.

antibody drug conjugates contract manufacturing Market Segmentations: